PDCD1 and colorectal carcinoma: The FDA approval of anti-PD-1 mAbs pembrolizumab and nivolumab, and anti-CTLA-4 mAb ipilimumab has improved the lives of many CRC patients and indicates the significant anti-cancer potential of IT.